Biomarkers research thread

A forum to discuss research on the origins of MS and its development.

Biomarkers research thread

Postby frodo » Sun Jul 09, 2017 5:55 am

Hi all,

Biomarkers can be used not only as a diagnosis, but also as a window to the underlying pathology. Therefore I start this thread about biomarkers, in which I will put the information that I can find.

Let's start with this one: "Molecular-Based Diagnosis of Multiple Sclerosis and Its Progressive Stages". They identify a set of 17 biomarkers

http://www.neurology.org/content/88/16_ ... .395.short

Results: A molecular diagnostic test of MS uses 17 variables to differentiate MS from all other conditions with the validated area under the receiver operating characteristic curve (AUC) of 0.95. This test is dominated by immunological biomarkers. Primary- and secondary-progressive MS are biologically indistinguishable, with quantitatively comparable intrathecal inflammation to RRMS. A molecular test that differentiates RRMS from progressive MS with a validated AUC=0.90 is based on 27 variables related to oligodendroglial and neuronal damage.

Conclusions: The identified molecular taxonomy maybe helpful in diagnostically challenging cases and provides opportunities for biomarker-supported drug development in MS. Our data are applicable to other CNS diseases.
User avatar
frodo
Family Elder
 
Posts: 843
Joined: Wed Dec 02, 2009 4:00 pm

Advertisement

Re: Biomarkers research thread

Postby frodo » Mon Jul 17, 2017 3:02 pm

Other biomarker under research, maybe pathogenic. The auto-antibody Kir4.1. Under study since 2012, it seems that one of its forms, (LG, lower glycosilated) is finally related to MS. This could amount up to an 28% of MS patients.

Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients

http://www.sciencedirect.com/science/ar ... 5916303957

Abstract

The presence of KIR4.1 antibodies has been proposed to be a characteristic of Multiple Sclerosis (MS). This could have a significant impact on disease management. However, the validation of the initial findings has failed till date. Conflicting results have been attributed to difficulties in isolating the lower-glycosylated (LG) KIR4.1 expressed in oligodendrocytes, the putative target antigen of autoantibodies.

The aim of this study is to verify the presence of KIR4.1 antibodies in MS patients, by independently replicating the originally-described procedure.

Assay procedure consisted of KIR4.1 expression in HEK293 cells, 3-step elution to isolate LG-KIR4.1 in elution fraction 3, and ELISA. Sera of 48 MS patients and 46 HCs were studied in 21 working sessions.

In a preliminary analysis, we observed different KIR4.1 antibody levels between MS patients and Healthy Controls (HCs). However, a high variability across working sessions was observed and the sensitivity of the assay was very low. Thus, stringent criteria were established in order to identify working sessions in which the pure LG-KIR4.1 was isolated. As per these criteria, we detected LG-KIR4.1 antibodies in 28% of MS patients and 5% of HCs.
User avatar
frodo
Family Elder
 
Posts: 843
Joined: Wed Dec 02, 2009 4:00 pm


Return to MS Etiology and Pathogenesis

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service